If you have traveled to any area in the US that is considered a “hot spot” with increasing amount of cases of COVID please alert our office before coming in for any appointment. All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Timothy A. McCarthy, MD

VCS Physicians

Timothy A. McCarthy, MD Headshot

“We are at an exciting time in the care of patients with cancer. We continue to have newer, better treatments – advancing our knowledge, enabling us to target these therapies more to each individual. At VCS you can be assured that you will receive state-of-the-art cancer care that is the best plan for you and your family.”

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology, Hematology and Internal Medicine

Fellowship

University of North Carolina Hospitals, Medical Oncology and Hematology

Residency

Rutgers Robert Wood Johnson Medical School

Medical School

Rutgers Robert Wood Johnson Medical School

College

Rutgers University

Dr. Timothy A. McCarthy graduated with high honors from Rutgers University where he received a Bachelor of Science in Materials Engineering.  He then went on to earn his medical degree and complete an Internal Medicine residency at Rutgers Robert Wood Johnson Medical School.  During his residency, Dr. McCarthy was honored with the Nilesh Tamakuwala, MD Memorial Award, a distinction presented to the individual who best demonstrated compassion in care and excellence in teaching.

Board-certified in Medical Oncology, Hematology and Internal Medicine, Dr. McCarthy completed his fellowship in Medical Oncology and Hematology at University of North Carolina Hospitals.  As an Oncology Fellow, Dr. McCarthy took a leadership role working with various departments with a specific interest in quality and process improvement projects.  Dr. McCarthy is a published author and has presented posters at various medical events, including the annual American Society of Clinical Oncology (ASCO) symposium.

Outside of medicine, Dr. McCarthy enjoys staying active and exploring the outdoors with his wife and 3 young children. He also enjoys listening to a diverse array of music and plays several different instruments.


Practice Blog

September 7, 2017

Timothy A. McCarthy, MD

Read More

Physician Publications

April 30, 2019

Fighting Brain Cancer at Virginia Cancer Specialists VCS:  Better Options, Better Outcomes -  Timothy A. McCarthy, MD

Read More
January 30, 2018

Northern Virginia 2018 Thoracic Oncology Symposium, CME Program - March 10th 2018

Read More
January 23, 2018

Boy Scout supports cancer patients with a very special Eagle Scout project

Read More

More Publications by Timothy A. McCarthy, MD

January 1, 2016

Importance of pharmacokinetic studies in the management of acquired factor X deficiency

Read More
July 14, 2014

Angiogenesis Inhibitors in Gastric Cancer

Read More

Clinical Trials (4)

Clinical Trial 20142

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NONƒ{SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTIƒ{PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY (GO41892)


Clinical Trial 19079

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)


Clinical Trial 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression


Clinical Trial D6070C00005

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab(MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Awards

January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018